News & Events
Press Releases
Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
Salubris Biotherapeutics Announces $32 Million Financing to Advance Novel Complex Biologics for Cardiovascular, Oncology, and Neurodegenerative Diseases
Upcoming Events
Past Events
Archived Events
Piper Sandler Virtual Cardio Day
2024/04/10
J.P. Morgan Healthcare Conference
2024/01/09
Cowen 43rd Annual Health Care Conference
2023/03/06